IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)

预防结核分枝杆菌中心 (IMPAC-TB) 的免疫机制

• 批准号: 10721327
• 负责人: KEVIN URDAHL
• 金额: $ 92.35万
• 依托单位: SEATTLE CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2026-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10721327
• 关键词: 2019-nCoV; Animal Model; Animals; Disease; Goals; HIV; Human; Immune; Immune Targeting; Immune response; Immunologics; Infection; Mycobacterium tuberculosis; Natural Immunity; Participant; Research Personnel; Tissues; Tuberculosis; Tuberculosis Vaccines; co-infection; cohort; improved; latent infection; multidisciplinary; nonhuman primate; prevent; programs; response; vaccination against tuberculosis; vaccine candidate; vaccine efficacy; vaccine strategy

The goal of this program is to establish an integrated multi-disciplinary team of highly collaborative investigators that will plan and conduct iterative, in-depth immunologic analyses of tissue-specific and systemic responses in small animals, non-human primates (NHPs), and humans to identify the key immune responses needed for protection against Mtb and to identify immunologic targets that can be used to improve TB vaccine strategies. This study will assess whether co-infection with SARS-CoV2 has a significant impact on innate immunity in study participants spanning the Mycobacterium tuberculosis (Mtb) infection spectrum.

该计划的目的是建立一个由高度协作的研究人员组成的综合多学科团队，该团队将对小动物，非人类灵长类动物（NHP）的组织特异性和全身反应进行迭代，深入的免疫学分析，并将人类识别出对MTB的保护所需的关键免疫反应，以确定能够确定免疫学的关键免疫反应，以确定免疫学。这项研究将评估与SARS-COV2的共感染是否对跨越结核分枝杆菌（MTB）感染谱系的研究参与者中的先天免疫有重大影响。